The present invention relates to a pharmaceutical composition suitable for oral administration of fingolimod, which composition exhibits improved stability and has advantageous properties in making orally administrable final dosage forms such as capsules or tablets. The composition comprises fingolimod or a pharmaceutically acceptable salt or ester thereof, tripotassium citrate and, optionally, a lubricant.